Rob Brierley

Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial Mirikizumab exhibited safety and efficacy in paediatric participants with moderately-to-severely active ulcerative colitis. These results support further evaluation of mirikizumab in the paediatric po...

New research - Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial

www.thelancet.com/journals/lan...

#GastroSky #MedSky #IBDSky

Development and validation of a machine-learning model to reduce futile procurements in donations after circulatory death in liver transplantation in the USA: a multicentre study We show that, compared with surgeon predictions and existing risk-prediction tools, our machine-learning model can enhance the accuracy of the prediction of progression to death in DCD donors and redu...

New at The Lancet Digital Health - Development and validation of a machine-learning model to reduce futile procurements in donations after circulatory death in liver transplantation in the USA: a multicentre study

www.thelancet.com/journals/lan...

#LiverSky #MedSky

Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis GLP-1 RAs, particularly Semaglutide and liraglutide, reduce alcohol use as measured by AUDIT scores and show beneficial effects on consumption, relapse, and alcohol-related morbidity. Mechanistic evid...

New @eClinicalMed - Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis

www.thelancet.com/journals/ecl...

#GastroSky #MedSky #EndoSky

Preprocedural screening for multidrug-resistant organisms in endoscopic retrograde cholangiopancreatography: an international, multicentre, cross-sectional observational study This study shows global heterogeneity in MDRO carriage among patients undergoing ERCP, reflecting underlying differences in antimicrobial resistance, healthcare infrastructure, and infection control p...

New @eclinicalmed.bsky.social - Preprocedural screening for multidrug-resistant organisms in endoscopic retrograde cholangiopancreatography: an international, multicentre, cross-sectional observational study

www.thelancet.com/journals/ecl...

#GastroSky #MedSky #IDSky #MicroSky

A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities Treatment efficacy in similar WH and SA IBD patients recruited to the UK IBD BioResource is unaffected by ethnicity but patients from SA ethnic backgrounds are at increased risk of developing pancreat...

New research @eClinicalMed - A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities

www.thelancet.com/journals/ecl...

#GastroSky #MedSky #IBDSky

Blue graphic promoting a Lancet Webinar with text saying: "Join Stephen Lam Chan, Professor at Chinese University of Hong Kong, for our global webinar on the global strategies to reverse the rise of liver cancer on Thursday, November 27, 2025, at 9am GMT/10am CET". A photograph of Stephen Lam Chan appears on the right-side of the graphic. Copyright: Elsevier Ltd.

Liver cancer cases will increase from 0.87 million in 2022 to 1.52 million in 2050.

Join Stephen Lam Chan to explore new strategies to treat liver cancer and how we can advance progress, together.

👉 Register now: hubs.li/Q03GK-q50

#oncology #hepatology #lgcw2025

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study Pemvidutide treatment met the primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks but did not meet the other primary endpoint of fibrosis improvement without worsening of MAS...

New @thelancet.com - Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

www.thelancet.com/journals/lan...

#LiverSky #MedSky #EndoSky

Blue graphic promoting a Lancet Webinar. Text saying: "Join Jian Zhou, Professor at Zhongshan Hospital, Fudan University, for our global webinar on global strategies to reverse the rise of liver cancer on Thursday, November 27, 2025 at 9am GMT/10am CET". A photograph of Professor Zhou appears on the right-side of the graphic. Copyright: Elsevier Ltd.

Liver cancer is the 6th most common cancer globally.

Join our webinar exploring The Lancet's Commission on addressing the global liver cancer burden and its comprehensive strategies from prevention to treatment.

👉 Register: hubs.li/Q03GK-q50

#oncology #hepatology #lgcw2025

The Lancet Summit: shaping the future of diabetes prevention. Image credit: Ixefra / Getty Images.

📣 Big news! We’re excited to announce the Advisory Board for The #LancetSummit: shaping the future of #diabetes prevention. Welcome Amanda Adler, Kamlesh Khunti, Dianna Magliano, Chantal Mathieu and Didac Mauricio Puente. Find out more and submit your abstract to join the Summit: hubs.li/Q03MV20T0

A special preview issue of The Lancet Regional Health – Africa. On the cover is a photograph of a doctor examining a Maasai baby. Copyright: Hugh Sitton/Getty Images.

🔔 Introducing The Lancet Regional Health – Africa, a new #goldopenaccess journal promoting the advancement of clinical practice and health policy in Africa.

Explore the new journal: ➡️ spkl.io/63325AbmLD #MedSky

Blue graphic with hexagon pattern. Text says: "The Lancet Webinars. Join Helena Wang, Asia Senior Executive Editor at The Lancet, for our global webinar on global strategies to reverse the rise of liver cancer on Thursday, November 27, 2025 at 9am GMT/10am CET". A photograph of Helena Wang appears on the right-hand side. Copyright: Elsevier Ltd.

What if we could find new ways to approach liver cancer prevention and treatment?

Join Helena Wang on Nov 27 to explore how we can work together to reverse the rise of this global health challenge.

👉 Register now: hubs.li/Q03GK-q50

#oncology #hepatology #lgcw2025

Incidence of non-colorectal/endometrial malignancies in individuals with #LynchSyndrome: a retrospective cohort study

40% of patients had non-CRC/ECs, with 11% of these cases diagnosed prior to undergoing genetic testing

www.thelancet.com/journals/ecl...
#MedSky

⭐New Series on #ChildhoodCancer in Asia now live!

Published collectively with @lancetchildadol.bsky.social, the 3 papers focus on challenges and opportunities for childhood cancer care in #Asia, which has half the global #paediatric #cancer burden

www.thelancet.com/series-do/childhood-cancer-asia

NEW RESEARCH—IgG4-related disease in the Japanese population: a whole-genome sequencing study bit.ly/4oVaGPm

Plus, linked Comment bit.ly/4hOOOmz
#Medsky #Rheumsky

Our December issue is out now at www.thelancet.com/journals/lan...

Content includes diet in GI disorders; IBS; IBD; oesophageal cancer; alcohol-related liver disease; MASLD + more!

#GastroSky #LiverSky #MedSky

Blue graphic with text saying: "The Lancet Webinars. Join our global webinar on the global strategies to reverse the rise of liver cancer on Thursday, November 27, 2025 at 9am GMT/10am CET. An image of a red liver in a blue body appears on the right of the graphic in a hexagonal frame. Copyright: Elsevier Ltd.

What if we could work together to change the future of liver cancer?

Join our webinar exploring how we can tackle the rising trend of liver cancer and differences in disease management across regions, hosted as part of London Global Cancer Week.

📆 Nov 27, 9am GMT
👉 Register: hubs.li/Q03GK-q50

Non-coeliac gluten sensitivity Non-coeliac gluten sensitivity (NCGS) refers to individuals who report intestinal and extraintestinal symptoms related to the ingestion of gluten-based or wheat-based foods, in the absence of coeliac ...

Non-coeliac gluten sensitivity (NCGS) remains a highly debated condition, despite ~10% of the global population self-reporting a gluten or wheat sensitivity.

A new Review examines current evidence & provides practical guidance for assessment and management: tinyurl.com/yjafmhc5

Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial Cilofexor did not significantly reduce the rate of fibrosis progression (vs placebo) in participants with non-cirrhotic PSC. A greater percentage of cilofexor-treated participants had pruritus than pl...

New research - Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial

www.thelancet.com/journals/lan...

#LiverSky #MedSky

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Linerixibat significantly improved pruritus versus placebo, supporting its potential to address a major symptom of PBC. An expected increase in diarrhoea in linerixibat-treated patients was observed.

New research - Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

www.thelancet.com/journals/lan...

#LiverSky #MedSky

🚨Our Nov issue is live - thelancet.com/issue/S1470-...

📊Articles: #breastcancer, #NSCLC, #prostatecancer, #melanoma

📰 Reviews: Tumour-infiltrating lymphocyte therapy in the era of genetic engineering AND AI for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO)

Attending #ACR25? Sophie Woolven, Deputy Editor, invites you to reach out with enquiries.

Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BLchR0 #Medsky #Rheumsky

In advance of our November issue, our latest editorial is now online

The next decade in #AMR: getting the basics right

www.thelancet.com/journals/lan...

#IDSky #ClinMicro #OpenAccess #OA

Real-time risk prediction model for sepsis in patients with acute GI bleeds: development and validation of a monitoring tool

This validated model effectively identifies patients with AGIB at high risk of sepsis, addressing an unmet need in emergency care

www.thelancet.com/journals/ecl...
#MedSky

Promotional card for the Lancet-Elsevier Foundation Evidence to Impact Award. Images depict two healthcare workers looking at a clipboard and a person facing into the sun with their eyes closed and holding their hand on their chest.

How does research drive real change?

Our new Lancet- @elsfoundation.bsky.social Evidence to Impact Award is open for proposals!

If your project champions implementation science, health equity, and community engagement, apply now: tinyurl.com/j5dty567

New research - Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study

www.thelancet.com/journals/lan...

#GastroSky #MedSky

Our November issue is live!

Including research on hip #osteoarthritis, #JIA, #BackPain, and #PsoriaticArthritis, plus much more! thelancet.com/journals/lan...
Cover by Sara Gironi Carnevale #Medsky #Rheumsky

Promotional card. Contact Sophie Woolven regarding content enquiries at sophie.woolven@lancet.com. Copyright: Elsevier Ltd.

Attending #ACR25? Sophie Woolven, Deputy Editor, invites you to reach out with enquiries.

Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BLchR0

Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases Given the unmet need of fatigue in primary biliary cholangitis (PBC), the PBC working group of the European Reference Network for Rare Liver Diseases assessed and summarised the current evidence relat...

New Review - Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases

www.thelancet.com/journals/lan...

#LiverSky #MedSky

New research - Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial

www.thelancet.com/journals/lan...

#GastroSky #MedSky #OncSky

Alcohol use disorders Alcohol use disorders consist of conditions characterised by compulsive heavy alcohol use and loss of control over alcohol intake. Alcohol use disorders are some of the most prevalent mental disorders...

Alcohol use disorders remain a major public health problem globally.

A new Seminar discusses the need for integrated alcohol control policies to improve the prevention of alcohol use disorders, improve access to treatment, and reduce stigma: tinyurl.com/395uf8f5